MedTrace Logo

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

NCT01493440 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2011-12-20

No results posted yet for this study

Summary

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Conditions

  • Repeated Implantation Failure

Interventions

DRUG

atosiban

Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.

Sponsors & Collaborators

  • Vietnam National University

    collaborator OTHER

  • An Sinh Hospital

    lead OTHER

Principal Investigators

  • Lan TN Vuong, MD · University of Medicine and Pharmacy of Ho Chi Minh City

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493440 on ClinicalTrials.gov